Sector: Healthcare | Industry: Biotechnology & Medical Research |
Company Contact | |
Address: | 1005-201 1st Ave S Saskatoon SK S7K 1J5 |
Tel: | N/A |
Website: | https://mustgrow.ca |
IR: | See website |
Key People | ||
Corey Giasson Chief Executive Officer, Director | Todd Lahti Chief Financial Officer, Corporate Secretary | Colin Bletsky Chief Operating Officer, Director |
Business Overview |
MustGrow Biologics Corp. is a Canada-based agricultural biotechnology company focused on providing science-based biological solutions for high-value crops. The Company is engaged in developing organic biocontrol, soil amendment and bio fertility products by harnessing the natural defense mechanism and organic materials of the mustard plant to sustainably protect the global food supply. It focuses on the development and commercialization of natural biological technologies and products from mustard seed for sustainable agricultural markets. The Company is providing a natural, organic technology platform with the efficacy of synthetic chemicals that has potential application in multiple global markets. Its technology pipeline includes soil amendment & bio fertility, biocontrol, and postharvest biocontrol & food preservation. The Company is pursuing the adoption and use of its technology in the soil amendment and bio fertility markets. |
Financial Overview |
For the nine months ended 30 September 2023, MustGrow Biologics Corp revenues decreased from C$6K to C$0K. Net loss decreased 10% to C$4.1M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Professional fees decrease of 54% to C$321K (expense), Stock-Based Compensation decrease of 18% to C$1.2M (expense). |
Reporting Currency: | Canadian Dollars |
Enterprise value: | $55.82M as of Sep 30, 2023 |
Annual revenue (TTM): | $0.00M as of Sep 30, 2023 |
EBITDA (TTM): | -$5.36M as of Sep 30, 2023 |
Net annual income (TTM): | -$5.11M as of Sep 30, 2023 |
Free cash flow (TTM): | -$3.87M as of Sep 30, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 50,076,271 as of Sep 30, 2023 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |